Loading…
Based on limited metadata, this warning letter was issued to Kelley-Ross Compounding Pharmacy, a pharmaceutical compounding operation, on July 30, 2018. While the specific violations cannot be detailed due to unavailable subject line information, the letter represents FDA enforcement action against a compounding pharmacy, which typically involves concerns related to preparation, quality, sterility, or distribution practices of compounded medications. The exact regulatory basis and specific violations addressed in this letter cannot be determined from the metadata provided.